Annual report pursuant to Section 13 and 15(d)

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses

v3.23.1
Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Schedule of Prepaid Expenses [Abstract]    
Litigation receivable (Note 11) $ 1,027,292 $ 1,937,693
Research and development expense tax credit receivable 546,563 644,513
Professional fees [1] 310,017 294,577
Value-added tax receivable 48,774 24,411
Taxes 25,634 25,634
Other 49,755
Total $ 1,958,280 $ 2,976,583
[1] In the previously filed Annual Report on Form 10-K for the year ended December 31, 2021, the Insurance line item above included $213,974 of expenses related to Oxford agreements for our CBR Pharma subsidiary. In the current year, those same expenses are grouped into the Professional fees grouping. As such, for comparative purposes, that amount has been moved from the Insurance grouping to the Professional fees grouping for the 2021 period.